Sensus Healthcare (NASDAQ:SRTS) used its fourth-quarter and full-year 2025 earnings call to emphasize a major regulatory and ...

Q4 2025 earnings call recap: revenue growth, 2026 guidance, Category 1 CPT impact, and BENEFIT-HF trial upside—read key takeaways.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological ...

Q4 2025 earnings call: new CMS CPT codes boost reimbursement visibility, Q1 2026 shipment outlook and 2026 profitability ...

Digital therapeutics developer Big Health announced Thursday that it has raised $23.7 million from notable investors betting ...

New investment fuels expansion as leading health systems adopt evidence-based digital care, driven by new billing codes and ...

CVRx, Inc. (NASDAQ: CVRX) ('CVRx'), a commercial-stage medical device company focused on developing, manufacturing and ...

Fourth quarter revenue growth of 12% and full year revenue growth of 14%Fourth quarter net income per diluted share of $4.66; adjusted net income ...

After seven years of developing the mental health artificial intelligence for providers and payers and investing in ...

Baird cut the stock to “neutral,” saying recent reimbursement developments have clouded visibility into future utilization and new account growth. The brokerage said it is harder to justify a higher ...

Nabla’s AI listens during patient visits and generates notes, assessment plans and patient instructions for providers.

CMS’ addition of more than 560 codes to the ASC covered procedure list for 2026 is a milestone for the industry, but SCA Health executives say the real impact, particularly for cardiovascular services ...